Stay updated with breaking news from Lon Onc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Oncimmune Holdings plc (LON:ONC – Get Rating) shares crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of GBX 40.19 ($0.50) and traded as low as GBX 37.40 ($0.47). Oncimmune shares last traded at GBX 37.40 ($0.47), with a volume of 1,636 shares trading […]
Director Deals - (ONC)
6 April 2021 | 07:44am StockMarketWire.com - Immunodiagnostics group Oncimmune said it had signed two separate agreements with Roche Pharmaceuticals and Cedars-Sinai Medical Center for use of the company's newly developed infectious disease panel. Oncimmune had in October announced the award of UK government funding for the development and validation of an infectious disease NavigAID panel. 'Utilising the data from this and other work, the company's current SeroTag research panel has been tailored to predict Covid-19 disease severity and therapeutic response to the virus and the effectiveness...
15 February 2021 | 07:54am StockMarketWire.com - Immunodiagnostics group Oncimmune posted a narrower first-half loss on the back of higher revenue and lower R&D spending. Pre-tax losses for the six months through November amounted to £2.8 million, compared to losses of £5.5 million year-on-year. Revenue rose to £1.8 million, up from £0.3 million. Oncimmune said it saw a 'marked increase in commercial activity' as large pharmaceutical and biotech companies utilised its biomarker discovery platform technology tools. Seven such contracts had been signed in the period, including with Roche Ph...
Genostics remains Oncimmune's exclusive partner in China and continues to work closely with Oncimmune to gain market entry